Pangaea Played Key Role in the Establishment of the Infectious Diseases Institute at Makerere University

Pangaea was approached by Pfizer and the Academic Alliance for AIDS Prevention and Care in Africa (“AA”) in May 2001 to act as the implementation partner for the Infectious Diseases Institute (“IDI”) project and to manage and administer the Pfizer grants awarded to establish, develop and operate IDI.

In its role as implementation partner, Pangaea was responsible for managing construction of the IDI building on-time and within budget, establishing the administrative and fiscal systems necessary for IDI programmes to run in a high quality and sustainable manner, and managing the implementation of IDI programmes.

An underlying principle guiding the development of IDI was to ensure that the Institute would become a sustainable, Ugandan-controlled entity. This goal guided every aspect of the project implementation from hiring and mentoring local staff and creating a building design that takes into account local conditions and materials, to establishing systems that can be supported locally.

The same principle of local control was evident in the process of transferring ownership of the Institute from Pangaea to Makerere University at the end of June 2005. Pangaea supported the efforts of Makerere University’s faculty of medicine and central administration to achieve a successful and seamless transfer of Institute ownership, governance, and management from Pangaea to the University.

About the Infectious Diseases Institute: "IDI is a centre of excellence, which is part of Uganda’s preeminent medical training institution, the Makerere University College of Health Sciences.  IDI is registered as a non-government organization, is owned by Makerere University, and is funded by both public and private resources.  IDI’s focus is strengthening care and treatment of HIV and related infectious diseases – for people living with HIV across Africa.  IDI facilitates this through offering high quality training for health workers; research on best practices related to HIV in low resource settings; and advanced clinical services that support the development of new models of care."